Skip to main
STTK

Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs (STTK) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Shattuck Labs Inc. is positioned favorably in the biotechnology sector due to its focus on innovative treatments for inflammatory bowel disease (IBD) and other immune-mediated conditions, with its lead program, SL-325, being a potential first-in-class therapeutic. The increasing adoption of biologics among patients with Crohn's Disease (CD) and Ulcerative Colitis (UC) in the U.S., rising from 22% to 44% and 5% to 16% respectively from 2007 to 2015, indicates a robust market demand for effective therapies, which supports Shattuck Labs's prospects. Additionally, the company's strategic development of SL-425 and multiple preclinical DR3-based bispecific antibodies reinforces its commitment to addressing unmet medical needs in IBD, potentially translating to significant market share growth as it builds on its strong efficacy and safety profile.

Bears say

Shattuck Labs Inc faces significant risks regarding the efficacy and safety of its lead programs, specifically the SL-325 and SL-425 candidates, as their success is uncertain and could be hindered by high immunogenicity or safety signals. Furthermore, the market growth and adoption rates for advanced therapies in inflammatory bowel disease (IBD) may be underestimated, which could negatively impact the commercial viability of their treatments. Lastly, a potential decline in surgery rates due to the increasing use of biologics may limit the patient population that could benefit from Shattuck's products, posing an additional challenge to their market prospects.

Shattuck Labs (STTK) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shattuck Labs (STTK) Forecast

Analysts have given Shattuck Labs (STTK) a Buy based on their latest research and market trends.

According to 4 analysts, Shattuck Labs (STTK) has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shattuck Labs (STTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.